Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Investigating the role of Chi3l1 in non-small cell lung cancer progression and resistance to immunotherapies
EF 2023-24
Résumé
Supervisor: Dr. William Muller, McGill University
Lung cancer is the most common type of cancer and the leading cause of cancer-related deaths in Canada, with less than 30% of patients surviving this cancer. Current therapies often fail, lead to recurrence or have devastating side effects. Immunotherapies, agents that harness the patients' immune system to fight tumors, are often used to treat lung cancers but with limited success. Improving response to immunotherapies requires us to understand how cancers suppress the immune system that is programmed to fight it. Recent data from our lab suggests that this may happen through a protein called Chitinase-3 like 1 (Chi3l1). We have previously shown that this protein prevents immune cells from attacking the cancer, leading to tumor growth.
In this project, I aim to investigate the role of Chi3l1 in lung cancer and evaluate its utility as a therapeutic target. I will use a mouse model that lacks Chi3l1 and direct therapeutic inhibition of Chi3l1 in order to understand how it manipulates the surrounding immune cells and how it impacts lung cancer advancement. Moreover, preclinical therapeutic experiments will investigate whether inhibiting Chi3l1 can improve response to immunotherapies. Bridging our pre-clinical analysis with clinical data, we will assess Chi3l1 levels in lung cancer patient samples and correlate it with response to immunotherapies. Our findings will thus shed light on the potential for Chi3l1 inhibition in addition to other immunotherapies as a treatment for lung cancers.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
495853
Name
Taifour Tarek
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Investigating the role of Chi3l1 in non-small cell lung cancer progression and resistance to immunotherapies
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chi3l1; Genetically Engineered Mouse Models; Immuno-Oncology; Immunotherapy; Lung Cancer; T Cell Exclusion; T Cells
Abstract
Supervisor: Dr. William Muller, McGill University
Lung cancer is the most common type of cancer and the leading cause of cancer-related deaths in Canada, with less than 30% of patients surviving this cancer. Current therapies often fail, lead to recurrence or have devastating side effects. Immunotherapies, agents that harness the patients' immune system to fight tumors, are often used to treat lung cancers but with limited success. Improving response to immunotherapies requires us to understand how cancers suppress the immune system that is programmed to fight it. Recent data from our lab suggests that this may happen through a protein called Chitinase-3 like 1 (Chi3l1). We have previously shown that this protein prevents immune cells from attacking the cancer, leading to tumor growth.
In this project, I aim to investigate the role of Chi3l1 in lung cancer and evaluate its utility as a therapeutic target. I will use a mouse model that lacks Chi3l1 and direct therapeutic inhibition of Chi3l1 in order to understand how it manipulates the surrounding immune cells and how it impacts lung cancer advancement. Moreover, preclinical therapeutic experiments will investigate whether inhibiting Chi3l1 can improve response to immunotherapies. Bridging our pre-clinical analysis with clinical data, we will assess Chi3l1 levels in lung cancer patient samples and correlate it with response to immunotherapies. Our findings will thus shed light on the potential for Chi3l1 inhibition in addition to other immunotherapies as a treatment for lung cancers.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Taifour, Tarek
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~